Semaglutid

Semaglutid is a drug ingredient used in weight-loss medications, specifically mentioned in recent news due to its evaluation by Stiftung Warentest, a German consumer organization. The organization found Semaglutid, marketed as Wegovy and administered via weekly injection, to be a suitable option for weight loss. According to their assessment, users of Semaglutid could achieve a 9-12% weight loss within a year, with the weight loss remaining largely stable after two years. The drug works by mimicking natural hormones, signaling satiety to the body. The news is relevant in the context of a growing market for weight-loss medications, including new oral options like Orforglipron, recently approved in the US. Semaglutid remains a significant player in this market, particularly as a tested and deemed effective injectable treatment.